Financing for Investcorp’s Acquisition of Stowe Family Law Holdings Limited
October 02, 2024
On September 25, 2024, Investcorp a leading global alternative investment firm, announced its acquisition of Stowe Family Law Holdings Limited, the largest specialist family law firm in the United Kingdom. Cravath represented Investcorp in the committed debt financing in connection with the transaction.
The Cravath team included partner Korey Fevzi, European counsels Jackson Lam and John Hutton and associates Lavinia J. Harrington and Hannah Hinzmann.
Related Practices & Industries
People
- Photo
-
-
LPC, 2001, College of Law of England and Waleswith Distinction
-
LL.B., 2000, Queen Mary University of London
- England & Wales
Education
Admitted In
- Photo
-
-
LL.B., 2001, Monash University
-
B.Com., 1998, Monash University
- England & Wales
Education
Admitted In
- Photo
-
-
LPC, 2012, Kaplan Law SchoolDistinction
-
LL.B., 2011, Newcastle UniversitySecond Class (Division I) Honours
- England & Wales
Education
Admitted In
Related News & Insights
Deals & Cases
February 13, 2025
Financing for Marlin Equity Partners’ Acquisition of EIDO Healthcare
On February 4, 2025, Marlin Equity Partners, a leading global investment firm, announced its acquisition of EIDO Healthcare, a leading provider of digital consent and patient information solutions. EIDO Healthcare will be combined with Radar Healthcare, an existing Marlin Equity Partners portfolio company and a provider of risk, quality, and compliance software for the healthcare and social care sectors. Cravath represented Marlin Equity Partners in the committed debt financing in connection with the transaction.
Deals & Cases
February 05, 2024
Artivion, Inc.’s Private Debt Financing
Cravath represented Artivion, Inc. in connection with $350 million of credit facilities obtained from Ares Management Credit funds to comprehensively address its debt maturities. Artivion is a medical device company focused on developing simple, elegant solutions that address cardiac and vascular surgeons’ most difficult challenges in treating patients with aortic diseases. The facilities consisted of a $190 million secured term loan facility, a $100 million secured delayed draw term loan facility and a $60 million secured revolving credit facility. The transaction closed on January 18, 2024.
